SCOR (SCR) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
4 Mar, 2026Executive summary
Achieved full-year net income of EUR 846 million to EUR 851 million and Return on Equity of 19.1% to 19.2% for 2025, both exceeding targets.
All business segments—P&C, Life & Health, and Investments—contributed to strong results, supported by disciplined execution of the Forward 2026 plan.
EUR 170 million in cost savings realized after two years, one year ahead of target, keeping management expenses flat year-over-year.
Proposed dividend of EUR 1.9 per share for 2025, up 5.6% from the previous year, establishing a new floor under the dividend ratchet policy.
Solvency ratio at 215%, at the upper end of the target range.
Financial highlights
Q4 2025 net income reached EUR 208 million (EUR 214 million adjusted), with an annualized ROE of 20.4% to 21.1%.
Full-year insurance revenue was EUR 15,378 million to EUR 15.4 billion, with management expenses at EUR 1,225 million.
FY 2025 combined ratio improved to 82.3% (down 4.0 pts YoY); Q4 2025 combined ratio at 80.9% (down 2.2 pts YoY).
Investment income on invested assets was EUR 209 million in Q4 and EUR 835 million for the year, with a return of 3.5% to 3.6%.
Operating cash flow for FY 2025 was EUR 1,169 million, up 29.5% year-over-year.
Outlook and guidance
Positive outlook for all business segments, supported by satisfactory January renewals and a diversified model.
Confident in maintaining a P&C combined ratio below 87% for 2026.
Regular income yield expected between 3.4% and 3.8% in 2026.
Continued focus on capital generation and disciplined underwriting, with growth as an outcome rather than a target.
L&H insurance service result exceeded updated Forward 2026 guidance.
Latest events from SCOR
- Q2 2024 net loss driven by L&H review, but P&C and solvency remain strong.SCR
Q2 202410 Feb 2026 - H1 2025 net income EUR 425m, ROE 20.3%, P&C combined ratio 82.5%, solvency 210%.SCR
Q2 202510 Feb 2026 - January 2026 renewals drove 14.8% EGPI growth and improved underwriting in a competitive market.SCR
Investor update4 Feb 2026 - Strong P&C and investment results offset by L&H review, solvency robust at 203%.SCR
Q3 202414 Jan 2026 - Forward 2026 targets 9% value growth, >12% ROE, higher-margin L&H, and robust solvency.SCR
Investor Day 202411 Jan 2026 - 9.6% EGPI growth driven by Specialty and Alternative Solutions, with stable profitability.SCR
Investor Update9 Jan 2026 - Q4 2024 net income EUR 233m, adjusted FY net income EUR 728m, solvency at 210%, dividend EUR 1.8.SCR
Q4 202413 Dec 2025 - Q1 2025 net income hit EUR 200m, with robust solvency and strong segment performance.SCR
Q1 202518 Nov 2025 - Q3 2025 delivered EUR 217m net income, 21.5%–22.1% ROE, and a 210% solvency ratio.SCR
Q3 20252 Nov 2025